This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
Real validated ETS2 Western blot protocols, expected-band and isoform facts, troubleshooting for weak or shifted signal, and recommended anti-ETS2 WB antibodies. Everything you need to plan the experiment before you commit precious samples.
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
| Expected band | ~53 kDa | |
| Gel | 12–15% (standard starting point) | |
| Negative control | Suggested KO / knockdown lysate |
| PTM | Phosphorylated | |
| Caveat | SPRY3 antibody mismatch | |
| Gene-set association | MSigDB Hallmark membership | |
| Isoform | 1 isoform(s) |
The A02641 protocol combines labelled catalog values with standard starting conditions. Published comparisons retain their own sample, reagent and detection scope.
| Sample / lysate | extracts of various cell lines, (catalog A02641) |
| Gel % | 12–15% (standard starting point) |
| Load | 20–30 µg total protein per lane; optimize for abundance (standard starting point) |
| Transfer | Standard semi-dry transfer; verify efficiency (standard starting point) |
| Membrane | 0.45 µm PVDF (standard starting point) |
| Blocking | Blocking buffer: 3% nonfat dry milk in TBST (catalog A02641) |
| Primary antibody | A02641 · 1:1000 (catalog A02641) |
| Primary incubation | Overnight at 4 °C (standard starting point) |
| Secondary antibody | Goat Anti-Rabbit IgG, 1:10000 (catalog A02641) |
| Secondary incubation | 1 h at room temperature (standard starting point) |
| Wash | 3 × 5 min in TBST (standard starting point) |
| Detection | ECL (catalog A02641) |
ETS2 is predicted at 53 kDa; its phosphoserines could affect mobility, but no migration shift or empirical band is demonstrated.
| Band near 53 kDa | Consistent with full-length ETS2, pending identity controls |
| Slightly slower band near 53 kDa | Could reflect phosphorylation, but a mobility shift is unproven |
| Close doublet near 53 kDa | Could reflect different phosphorylation states, pending phosphatase testing |
| Stronger band in nuclear extract | Consistent with the reported nuclear location |
| Predicted molecular mass | Full-length ETS2 is predicted at 53 kDa |
| Phosphoserines 220 and 225 | May affect mobility; no shift is established |
| Phosphoserines 295 and 298 | May affect mobility; no shift is established |
| Phosphoserine 301 | May affect mobility; no shift is established |
| Situation | Likely cause | Next action |
|---|---|---|
| No band in lysate | Nuclear ETS2 may be underrepresented in the sample | Check nuclear enrichment and a positive-control lysate |
| Band higher than expected | Phosphorylation could affect mobility, but the cause is unestablished | Compare phosphatase-treated and untreated samples and verify band identity |
| Band lower than expected | Possible degradation; no cleavage feature is listed | Check sample handling and confirm with an independent ETS2 antibody |
| Multiple bands | Different phosphorylation states are possible but unproven | Compare phosphatase-treated samples and use an independent ETS2 antibody |
| Weak or no signal | The nuclear target may be insufficiently represented | Enrich the nuclear fraction and check the antibody with a positive control |
| Fragments below expected size | Possible sample proteolysis | Use fresh lysate with protease inhibitors and confirm fragment identity |
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| No high/medium HPA tissues identified in the supplied evidence. | ||||
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| No lower-expression tissue rows available in the supplied evidence. | ||||
Deeper troubleshooting and optimisation questions for ETS2, answered from its protein features.
Catalog antibodies with Western blot application and product-specific WB images. Evaluate suitability with the reported sample, controls and experimental conditions.
A02641 is the listed anti-ETS2 antibody, with reported human, mouse and rat reactivity. Its WB image caption describes various cell lines but names SPRY3 antibody, so the image does not clearly establish ETS2 WB validation.
Which to pick: Only A02641 is listed. It has a WB image, but the SPRY3 caption makes that evidence ambiguous; confirm the antibody identity and suitability for your samples before use.